title: Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.
abstract: We report on prognostic implications for post-relapse survival (PRS) of a gene expression profiling (GEP)-defined risk score at relapse available in 120 myeloma patients previously enrolled in tandem transplantation trial Total Therapy 2. Among the 71 patients with additional GEP baseline information, 3-year PRS was 71% in 40 patients with low risk present both at baseline and relapse contrasting with only 17% in 28 patients with high risk at relapse, 12 of whom with baseline low-risk status fared better than the remainder (P = .08). On multivariate analysis of relapse parameters available in 104 patients, high risk conferred short PRS (hazard ratio = 4.00, P < .001, R(2) = 33%), whereas relapse hyperdiploidy predicted long PRS (hazard ratio = 0.37, P = .022, cumulative R(2) = 41%). In case the initial partial response lasted less than 2 years, relapse low-risk identified 26 patients with superior 3-year PRS of 61% versus 9% among 32 with relapse high-risk (P < .001). Based on its PRS predictive power, GEP analysis should be an integral part of new agent trials in search of better therapy for high-risk myeloma.
authors.affiliation: Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA.
authors.forename: Bijay
authors.initials: B
authors.lastname: Nair
authors.forename: John D
authors.initials: JD
authors.lastname: Shaughnessy
authors.forename: Yiming
authors.initials: Y
authors.lastname: Zhou
authors.forename: Marie
authors.initials: M
authors.lastname: Astrid-Cartron
authors.forename: Pingping
authors.initials: P
authors.lastname: Qu
authors.forename: Frits
authors.initials: F
authors.lastname: van Rhee
authors.forename: Elias
authors.initials: E
authors.lastname: Anaissie
authors.forename: Yazan
authors.initials: Y
authors.lastname: Alsayed
authors.forename: Sarah
authors.initials: S
authors.lastname: Waheed
authors.forename: Klaus
authors.initials: K
authors.lastname: Hollmig
authors.forename: Jackie
authors.initials: J
authors.lastname: Szymonifka
authors.forename: Nathan
authors.initials: N
authors.lastname: Petty
authors.forename: Antje
authors.initials: A
authors.lastname: Hoering
authors.forename: Bart
authors.initials: B
authors.lastname: Barlogie
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics; D014411:Neoplastic Stem Cells / Q000378:metabolism*; D010950:Plasma Cells / Q000378:metabolism*; D011123:Polyploidy; D011379:Prognosis; D016016:Proportional Hazards Models; D018570:Risk Assessment; D016879:Salvage Therapy
chemical_list: D009363:Neoplasm Proteins